Robustness of the Comparative Observational Evidence Supporting Class I and II Cardiac Surgery Procedures

Mario Gaudino, MD; Irbaz Hameed, MD; N. Bryce Robinson, MD; Ajita Naik, MD; Viola Weidenmann, MD; Yongle Ruan, MD; Derrick Tam, MD; Leonard N. Girardi, MD; Stephen Fremes, MD

BACKGROUND: Current cardiac surgery guidelines give Class I and II recommendations to valve-sparing root replacement over the Bentall procedure, mitral valve (MV) repair over replacement, and multiple arterial grafting with bilateral internal thoracic artery based on observational evidence. We evaluated the robustness of the observational studies supporting these recommendations using the E value, an index of unmeasured confounding.

METHODS AND RESULTS: Observational studies cited in the guidelines and in the 3 largest meta-analyses comparing the procedures were evaluated for statistically significant effect measures. Two E values were calculated: 1 for the effect-size estimate and 1 for the lower limit of the 95% CI. Thirty-one observational studies were identified, and E values were computed for 75 effect estimates. The observed effect estimates for improved clinical outcomes with valve-sparing root replacement versus the Bentall procedure, MV repair versus replacement, and grafting with bilateral internal thoracic artery versus single internal thoracic artery could be explained by an unmeasured confounder that was associated with both the treatment and outcome by a risk ratio of more than 16.77, 4.32, and 3.14, respectively. For MV repair versus replacement and grafting with bilateral internal thoracic artery versus single internal thoracic artery, the average E values were lower than the effect sizes of the other measured confounders in 33.3% and 60.9% of the studies, respectively. For valve-sparing root replacement versus the Bentall procedure, no study reported effect sizes for associations of other covariates with outcomes.

CONCLUSIONS: The E values for observational evidence supporting the use of valve-sparing root replacement, MV repair, and grafting with bilateral internal thoracic artery over the Bentall procedure, MV replacement, and grafting with single internal thoracic artery are relatively low. This suggests that small-to-moderate unmeasured confounding could explain most of the observed associations for these procedures.

Key Words: cardiac surgery ■ E value ■ guideline ■ guideline adherence

Randomized controlled trials are the standard for comparing the treatment effects of different surgical procedures. However, randomized evidence is available only for a minority of questions in cardiac surgery and surgeons often must rely on observational evidence. Current guidelines recommend (Class I; Level of Evidence C) valve-sparing root replacement (VSRR) over the Bentall procedure, when possible, for patients with proximal aortic aneurysms. Similarly, mitral valve (MV) repair is recommended over replacement in patients with degenerative mitral regurgitation as a Class I, Level of Evidence C recommendation. In coronary surgery, multiple arterial grafting with bilateral internal thoracic artery (BITA) is a Class Ila, Level of Evidence B recommendation in patients not at increased risk of sternal wound infection. All these recommendations are solely based on observational evidence (notably for grafting with BITA; in fact, the only randomized trial suggested lack of effect).
However, observational studies may be confounded by treatment allocation bias. Although stratification, propensity matching, and regression-based adjustments can adjust for assumed and measured confounders, there is potential for unmeasured confounders. Strategies to minimize unmeasured confounding such as the negative control method, the perturbation variable method, instrumental variable methods, sensitivity analysis, and ecological analysis require informed assumptions and are complex to perform hence, their use in clinical research is very limited.

The E value is a method used to analyze unmeasured confounding in observational studies by objectively quantifying the minimum strength of association on the risk ratio scale that an unmeasured confounder must have with both the treatment and outcome, while simultaneously considering measured covariates, to negate the observed treatment-outcome association. Importantly, the E value does not require assumptions on the nature or prevalence of the unmeasured confounder(s). We evaluated the robustness of observational studies comparing VSRR versus the Bentall procedure, MV repair versus replacement, and BITA versus single internal thoracic artery (SITA) grafting using the E value.

What Is New?
• The E values for observational evidence supporting the use of valve-sparing root replacement, mitral valve repair, and grafting with bilateral internal thoracic artery over the Bentall procedure, mitral valve replacement, and grafting with single internal thoracic artery are relatively low.
• This suggests that small-to-moderate unmeasured confounding could explain most of the observed associations for these procedures.

What Are the Clinical Implications?
• The E value, or other similar sensitivity analyses, should be part of the reporting of all comparative observational studies.

Nonstandard Abbreviations and Acronyms
BITA bilateral internal thoracic artery
MV mitral valve
SITA single internal thoracic artery
VSRR valve-sparing root replacement

Calculation of E Value
Using previously described methodology for each effect measure, 2 E values were calculated: 1 for the effect-size estimate and 1 for the lower limit of the 95% CI. For consistency, effect estimates were inverted where necessary, so that all relative effects were >1. For a RR, the E value was estimated as RR+√[RR×(RR−1)], with RR being the observed risk ratio estimate after adjustments for measured confounders. For an OR or HR, RR in the previous formula was replaced by OR or HR when the outcome was uncommon (<15%). If the outcome was common (≥15%), RR was replaced with √OR for the OR and by (1−0.5√HR)/(1−0.5√1/HR) for the HR.

All calculations were performed using R version 3.4.3 (R Foundation for Statistical Computing, Vienna, Austria) and using the EValue and pairwiseCI packages.

Statistical Analysis
Following calculation of E values for each effect measure, the averages of the E values for the different treatment-outcome effect measures, and the corresponding lower CI limits for each surgical comparison
were calculated. These were compared with the effect measures for associations of other covariates with study outcomes for each observational study reporting the surgical comparison.

For each surgical comparison, the averages of the E values of effect measures and the corresponding lower CI limits were also calculated based on type of clinical outcome, and study strategy for adjustment of confounders (none, multivariable adjustment, propensity matching, and propensity matching and multivariable adjustment [doubly robust]).

**RESULTS**

**Study Characteristics**

Thirty-one observational studies were identified: 4 comparing VSRR versus the Bentall procedure, 7 comparing MV repair versus replacement, and 20 comparing BITA versus SITA grafting. Twelve studies were from the United States, 5 from Canada, 3 from Japan, and the rest from other countries. E values were computed for 75 effect estimates and 64 lower CI limits (Figure 1). The details of study characteristics and the effect estimate of covariates reported for each study are summarized in Table 1.13–43

**VSRR Versus the Bentall Procedure**

In the 4 studies comparing VSRR versus the Bentall procedure, the sample size ranged from 135 to 616 patients. One was propensity matched, 1 used both propensity matching and multivariable adjustment, and 2 used multivariable adjustment. On average, the observed effect estimates for improved clinical outcomes with VSRR versus the Bentall procedure could be explained by an unmeasured confounder that was associated with both VSRR and the clinical outcomes by a risk ratio of more than 16.77 (E value for lower confidence bound 2.44). No study reported effect sizes for associations of other covariates with study outcomes. The mean E value for effect estimates in propensity-matched studies was highest (22.08), followed by multivariable-adjusted (17.14) studies, and propensity-matched and multivariable-adjusted (15.60) studies. Details of the mean E values for the effect estimates of different clinical outcomes for VSRR versus the Bentall procedure are summarized in Table 2.

**MV Repair Versus Replacement**

In the 7 studies comparing MV repair versus replacement, the sample size ranged from 183 to 1922 patients. One was propensity matched, and 6 used multivariable adjustment. On average, the observed effect estimates for improved clinical outcomes with MV repair versus the MV replacement could be explained by an unmeasured confounder that was associated with both MV repair and the clinical outcomes by an effect size of >4.32. This was lower than the effect size of the other measured confounders in 33.3% of the observational studies comparing MV repair versus replacement (E value for lower confidence bound 1.74). In terms of an adjustment strategy for the computation of treatment effects, the mean E value for effect estimates in multivariable adjusted studies was highest (4.49), followed by propensity-matched studies (3.59). There were no studies that used both propensity matching and multivariable adjustment. Details of the average E values for the effect estimates of different clinical outcomes for MV repair versus replacement are summarized in Table 2.
Table 1. Demographics of Patients in the Included Studies

| Study                  | Institution                               | Country         | Study Period | No. of Patients | Type of Adjustment | Effect Estimates of Other Confounders Reported in Study |
|------------------------|-------------------------------------------|-----------------|--------------|-----------------|-------------------|--------------------------------------------------------|
| Benedetto et al, 2014  | Harefield Hospital, London                | United Kingdom  | 2001–2013    | 4195 (750 BITA grafts, 3445 SITA grafts) | PSM               | Outcome: death • No prior MI: HR, 0.48; 95% CI, 0.23–0.98 • LVEF <50: HR, 0.18; 95% CI, 0.05–0.60 |
| Berreklouw et al, 2001 | Catharina Hospital                        | The Netherlands | 1985–1990    | 482 (249 BITA, 233 SITA) | Multivariable adjustment | Outcome: angina • Female sex: RR, 1.9; 95% CI, 1.2–3.0 Outcome: angina-free survival • Age: RR, 1.0; 95% CI, 1.0–1.1 |
| Buxton et al, 1998     | Austin and Repatriation Medical Center    | Australia       | 1985–1995    | 2853 (1296 BITA grafts, 1557 SITA grafts) | Multivariable adjustment | Outcome: death • PVD: RR, 2.4; 95% CI, 1.7–3.4 • Prior MI: RR, 2.1; 95% CI, 1.6–3.1 • Severe left ventricular dysfunction: RR, 3.9; 95% CI, 2.6–5.9 • Moderate left ventricular dysfunction: RR, 2.0; 95% CI, 1.5–2.6 • Age >/=70 y: RR, 3.4; 95% CI, 2.4–4.8 • Age 60–69 y: RR, 1.7; 95% CI, 1.3–2.4 • DM: RR, 1.7; 95% CI, 1.3–2.4 • Carotid disease: RR, 1.7; 95% CI, 1.2–2.4 Outcome: composite of all cause mortality, late myocardial infarction, or late reoperation • PVD: RR, 2.4; 95% CI, 1.5–2.9 • Prior MI: RR, 2.1; 95% CI, 1.3–2.2 • Severe left ventricular dysfunction: RR, 3.1; 95% CI, 2.1–3.4 • Moderate left ventricular dysfunction: RR, 2.0; 95% CI, 1.5–2.6 • Age >/=70 y: RR, 3.4; 95% CI, 1.8–3.7 • Age 60–69 y: RR, 1.3; 95% CI, 1.0–1.7 • DM: RR, 1.7; 95% CI, 1.3–2.2 |
| Calafiore et al, 2005   | Multicenter                               | Italy           | 1986–1999    | 1602 (1026 BITA, 576 SITA) | PSM and multivariable adjustment | NR |
| Carrier et al, 2009    | Montreal Heart Institute                  | Canada          | 1995–2007    | 6655 (1235 BITA grafts, 5420 SITA grafts) | Multivariable adjustment | Outcome: death • Age: HR, 1.06; 95% CI, 1.05–1.07 • Sex: HR, 0.90; 95% CI, 0.78–1.04 • DM: HR, 1.63; 95% CI, 1.43–1.86 • Hyperlipidemia: HR, 0.83; 95% CI, 0.73–0.95 • Antiplatelet agents: HR, 0.83; 95% CI, 0.73–0.95 • Beta-blocker: HR, 0.74; 95% CI, 0.65–0.85 • ACE-inhibitor: HR, 1.22; 95% CI, 1.05–1.42 • Statin: HR, 0.73; 95% CI, 0.67–0.86 |
| Chikwe et al, 2011     | Mount Sanai Medical Center, Herzzentrum Universitaet | United States, Germany | 1998–2008    | 322 (227 MVr, 95 MVR) | Multivariable adjustment | Outcome: survival • Age: HR, 1.1; 95% CI, 1.0–1.2 • LVEF ≤30%: HR, 1.8; 95% CI, 1.0–3.3 • Renal failure: HR, 1.8; 95% CI, 1.1–2.8 • Emergency surgery: HR, 2.9; 95% CI, 1.6–5.2 |
| Endo et al, 2001       | Tokyo Women’s Medical University          | Japan           | 1985–1998    | 1131 (443 BITA grafts, 688 SITA grafts) | Multivariable adjustment | NR |
| Gogbashian et al, 2005 | Brigham and Women’s Hospital              | United States   | 1992–2002    | 183 (147 MV, 36 MVR) | Multivariable adjustment | Outcome: death • NYHA III/IV cardiac failure (vs II/IV): HR, 0.52; 95% CI, 0.32–0.86 • COPD: HR, 2.79; 95% CI, 1.47–5.28 • Cerebrovascular disease: HR, 1.52; 95% CI, 1.31–1.93 • Hypercholesterolemia: HR, 2.07; 95% CI, 1.24–3.46 • Chronic renal insufficiency: HR, 1.76; 95% CI, 1.22–2.57 • MVR and CABG: HR, 1.66; 95% CI, 1.03–2.67 • Postoperative pneumonia: HR, 1.62; 95% CI, 1.35–2.18 • Postoperative stroke: HR, 1.64; 95% CI, 1.11–2.60 |

(Continued)
| Study         | Institution                                      | Country     | Study Period  | No. of Patients | Type of Adjustment | Effect Estimates of Other Confounders Reported in Study |
|--------------|--------------------------------------------------|-------------|---------------|----------------|-------------------|--------------------------------------------------------|
| Grau et al, 2015<sup>21</sup> | The Valley Heart Center                          | United States | 1994–2013     | 6666 (1544 BITA grafts, 5122 SITA grafts) | PSM and multivariable adjustment | Outcome: death  
  - LVEF (%): HR, 0.97; 95% CI, 0.96–0.98  
  - Age: HR, 1.08; 95% CI, 1.06–1.09  
  - DM: HR, 1.59; 95% CI, 1.15–2.20  
  - PVD: HR, 1.70; 95% CI, 1.28–2.27  
  - History of renal failure: HR, 3.39; 95% CI, 1.42–8.04  
  - History of smoking: HR, 1.41; 95% CI, 1.10–1.81  
  - Surgery era (early reference) 2001–2006: HR, 0.65; 95% CI, 0.45–0.93  
  - Total grafts placed: HR, 0.84; 95% CI, 0.74–0.97  
  - Blood transfusion at surgery: HR, 1.43; 95% CI, 1.13–1.82 |
| Itoh et al, 2016<sup>22</sup> | Saitama Medical Center                           | Japan       | 1990–2014     | 400 (107 BITA grafts, 293 SITA grafts) | PSM NR |
| Javadikasgari et al, 2017<sup>23</sup> | Cleveland Clinic                                 | United States | 1985–2011    | 1071 (872 MVr, 199 MVR) | Multivariable adjustment NR |
| Kelly et al, 2012<sup>24</sup> | Queen Elizabeth II Health Sciences Center        | Canada      | 1995–2007     | 7633 (1079 BITA, 6554 SITA) | Multivariable adjustment | Outcome: survival  
  - No ITA: HR, 1.42; 95% CI, 1.24–1.62  
  - Incomplete revascularization: HR, 1.23; 95% CI, 1.10–1.38  
  - Age 60–69 y: HR, 1.75; 95% CI, 1.49–2.06  
  - Age 70–79 y: HR, 2.96; 95% CI, 2.52–3.48  
  - Age ≥80 y: HR, 4.88; 95% CI, 3.96–5.98  
  - BMI <25: HR 1.20, 95% CI 1.07–1.34  
  - BMI >35: HR, 1.22; 95% CI, 1.04–1.43  
  - DM: HR, 1.50; 95% CI, 1.35–1.66  
  - Renal function: HR, 2.03; 95% CI, 1.78–2.36  
  - PVD: HR, 1.69; 95% CI, 1.52–1.88  
  - COPD: HR, 1.66; 95% CI, 1.48–1.85  
  - LVEF <40%: HR, 1.80; 95% CI, 1.60–2.02  
  - In-hospital urgent: HR, 1.34; 95% CI, 1.19–1.52  
  - Urgent: HR, 1.78; 95% CI, 1.54–2.05  
  - Emergency: HR, 1.83; 95% CI, 1.48–2.26 |
| Kieser et al, 2011<sup>25</sup> | The Province of Alberta                          | Canada      | 1995–2008     | 5067 (1038 BITA grafts, 4029 SITA grafts) | Multivariable adjustment NR |
| Kinoshita, 2015<sup>26</sup> | Shiga University of Medical Science              | Japan       | 2002–2014     | 1203 (750 BITA grafts, 453 SITA grafts) | PSM and multivariable adjustment only | Outcome: death (PSM and multivariable adjusted)  
  - Age per 1-SD increase: HR, 1.40; 95% CI, 1.12–1.75  
  - BMI: HR, 0.79; 95% CI, 0.67–0.93  
  - End-stage renal failure: HR, 3.02; 95% CI, 1.97–4.63  
  - Peripheral arterial disease: HR, 1.90; 95% CI, 1.26–2.87  
  - Prior MI: HR, 1.93; 95% CI, 1.31–2.84  
  - Outcome: cardiac death (PSM and multivariable adjusted)  
  - End-stage renal failure: HR, 8.08; 95% CI, 4.23–15.43  
  - Peripheral arterial disease: HR, 2.71; 95% CI, 1.43–5.14  
  - Prior MI: HR, 2.99; 95% CI, 1.57–5.69  
  - Heart failure: HR, 1.95; 95% CI, 1.04–3.66  
  - Outcome: death (multivariable adjusted)  
  - Age per 1-SD increase: HR, 1.38; 95% CI, 1.13–1.68  
  - End-stage renal failure: HR, 3.49; 95% CI, 2.38–5.12  
  - Peripheral arterial disease: HR, 2.26; 95% CI, 1.57–3.25  
  - Prior MI: HR, 1.76; 95% CI, 1.24–2.50  
  - Heart failure: HR, 1.61; 95% CI, 1.02–2.52  
  - Outcome: cardiac death (multivariable adjusted)  
  - End-stage renal failure: HR, 6.80; 95% CI, 3.74–12.37  
  - Peripheral arterial disease: HR, 2.45; 95% CI, 1.34–4.47  
  - Prior MI: HR, 2.58; 95% CI, 1.42–4.69 |
### Table 1. Continued

| Study                        | Institution                                      | Country       | Study Period | No. of Patients | Type of Adjustment | Effect Estimates of Other Confounders Reported in Study |
|------------------------------|--------------------------------------------------|---------------|--------------|------------------|-------------------|--------------------------------------------------------|
| Kurlansky, 2010²⁷            | Florida Heart Research Institute                  | United States | 1972–1994    | 4584 (2215 BITA, 2369 SITA) | PSM and multivariable adjustment | Age: HR, 1.06; 95% CI, 1.06–1.07  
  Angina-stable: HR, 0.89; 95% CI, 0.82–0.97  
  Cardiac arrest: HR, 1.59; 95% CI, 1.20–2.11  
  CHF: HR, 1.44; 95% CI, 1.28–1.62  
  Cerebrovascular disease: HR, 1.45; 95% CI, 1.22–1.73  
  DM: HR, 1.52; 95% CI, 1.39–1.66  
  Dyslipidemia: HR, 0.87; 95% CI, 0.76–0.98  
  LVEF: HR, 1.33; 95% CI, 1.22–1.45  
  Female sex: HR, 0.88; 95% CI, 0.80–0.97  
  LM disease: HR, 1.17; 95% CI, 1.06–1.30  
  Prior MI: HR, 1.23; 95% CI, 1.14–1.34  
  Pulmonary insufficiency: HR, 1.35; 95% CI, 1.14–1.61  
  PVD: HR, 1.47; 95% CI, 1.24–1.73  
  Renal disease: HR, 1.44; 95% CI, 1.19–1.73  
  Perfusion time: HR, 1.00; 95% CI, 1.00–1.00  
  Renal insufficiency: HR, 1.99; 95% CI, 1.58–2.50  
  MI: HR, 1.42; 95% CI, 1.20–1.69 |
| Lazam et al, 2017²⁸          | Multicenter Multinational                         | United States | 1980–2005    | 1922 (1922 MVr, 213 MVR) | PSM NR | Outcome: death  
  Age >70 y: HR, 2.1; P=0.025  
  LVEF <40%: HR, 2.1; P=0.030  
  NYHA III or IVHR, 4.8; P=0.004  
  Outcome: Heart failure  
  Age >70 y: HR, 2.5; P=0.012  
  LVEF <40%: HR, 2.8; P=0.006  
  NYHA III or IV: HR, 5.0; P=0.010  
  Outcome: anticoagulation-related hemorrhage  
  Age >70 y: HR, 6.3; P=0.0059 |
| Lee et al, 1997²³            | Papworth Hospital Regional Cardiac Center        | United Kingdom | 1987–1994    | 278 (167 MVr, 111 MVR) | Multivariable adjustment | Age >70 y: HR, 2.1; P=0.025  
  LVEF ≤40%: HR, 2.1; P=0.030  
  NYHA III or IV: HR, 4.8; P=0.004  
  Outcome: death  
  Age >70 y: HR, 2.5; P=0.012  
  LVEF <40%: HR, 2.8; P=0.006  
  NYHA III or IV: HR, 5.0; P=0.010  
  Outcome: Heart failure  
  Age >70 y: HR, 2.5; P=0.012  
  LVEF <40%: HR, 2.8; P=0.006  
  NYHA III or IV: HR, 5.0; P=0.010  
  Outcome: anticoagulation-related hemorrhage  
  Age >70 y: HR, 6.3; P=0.0059 |
| Lee et al, 2018²⁰            | Seoul National University Bundang Hospital       | South Korea   | 1995–2013    | 216 (82 VSSR, 134 Bentall) | PSM, multivariable adjustment | Age >70 y: HR, 2.1; P=0.025  
  LVEF ≤40%: HR, 2.1; P=0.030  
  NYHA III or IV: HR, 4.8; P=0.004  
  Outcome: death  
  Age >70 y: HR, 2.5; P=0.012  
  LVEF <40%: HR, 2.8; P=0.006  
  NYHA III or IV: HR, 5.0; P=0.010  
  Outcome: anticoagulation-related hemorrhage  
  Age >70 y: HR, 6.3; P=0.0059 |
| Locker et al, 2012³¹         | Mayo Clinic                                      | United States | 1993–2009    | 8295 (860 BITA grafts, 7435 SITA grafts) | Multivariable adjustment | Age >70 y: HR, 1.07; 95% CI, 1.06–1.07  
  Low LVEF (per 1%): HR, 1.02; 95% CI, 1.02–1.01  
  Hypertension: HR, 1.14; 95% CI, 1.05–1.25  
  DM: HR, 1.55; 95% CI, 1.44–1.68  
  Chronic lung disease: HR, 1.66; 95% CI, 1.50–1.83  
  Renal failure: HR, 2.29; 95% CI, 2.01–2.62  
  PVD: HR, 1.45; 95% CI, 1.34–1.57  
  MI: HR, 1.10; 95% CI, 1.02–1.19  
  OCA: HR, 1.56; 95% CI, 1.38–1.76  
  LM disease >50%: HR, 1.17; 95% CI, 1.08–1.26  
  Urgent/emergent: HR, 1.11; 95% CI, 1.01–1.21  
  OPCAB: HR, 1.30; 95% CI, 1.11–1.52 |
| Medalion et al, 2010³²       | Tel Aviv Sourasky Medical Center                 | Israel        | 1996–2008    | 1627 (1045 BITA grafts, 582 SITA grafts) | Multivariable adjustment | Age 80 y: HR, 0.50; 95% CI, 0.41–0.61  
  Age 75–79 y: HR, 0.73; 95% CI, 0.62–0.81  
  DM: HR, 0.73; 95% CI, 0.64–0.84  
  COPD: HR, 0.58; 95% CI, 0.47–0.72  
  CHF: HR, 0.66; 95% CI, 0.55–0.77  
  Emergency operation: HR, 0.80; 95% CI, 0.68–0.99  
  PVD: HR, 0.80; 95% CI, 0.69–0.95  
  CVD: HR, 0.80; 95% CI, 0.67–0.96  
  Repeat operation: HR, 0.50; 95% CI, 0.35–0.70  
  Conduit—RA: HR, 1.56; 95% CI, 1.10–1.99 |

(Continued)
| Study | Institution | Country | Study Period | No. of Patients | Type of Adjustment | Effect Estimates of Other Confounders Reported in Study |
|-------|-------------|---------|--------------|----------------|-------------------|-----------------------------------------------------|
| Navia, 2016 | Instituto Cardiovascular de Buenos Aires | Argentina | 1996–2014 | 2486 (2098 BITA, 388 SITA) | Multivariable adjustment | Outcome: death  
  • Age years: HR, 1.07; 95% CI, 1.06–1.08  
  • DM: HR, 1.69; 95% CI, 1.39–2.06  
  • Cerebrovascular disease: HR, 2.16; 95% CI, 1.49–3.11  
  • Previous renal dysfunction: HR, 2.12; 95% CI, 1.58–2.85  
  • Smoking habit: HR, 1.47; 95% CI, 1.21–1.78  
  • Elective operation: HR, 0.78; 95% CI, 0.64–0.94  
  • Left ventricular dysfunction (moderate/severe): HR, 2.47; 95% CI, 1.92–3.19 |
| Ouzounian et al, 2016 | Peter Munk Cardiac Centre | Canada | 1990–2010 | 616 (253 VSRR, 363 Bentall) | Multivariable adjustment | NR |
| Parsa et al, 2013 | Duke University Medical Center | United States | 1984–2009 | 17 609 (728 BITA grafts, 16 881 SITA grafts) | Multivariable adjustment | NR |
| Pettinari et al, 2015 | Multicenter | Belgium | 1972–2006 | 3496 (1328 BITA grafts, 2168 SITA grafts) | PSM | Outcome: death  
  • Experience: OR, 0.68; 95% CI, 0.58–0.81  
  • Age: OR, 1.04; 95% CI, 1.00–1.07  
  • Preop dialysis: OR, 0.07; 95% CI, 0.01–0.40  
  • Preop creatinine: OR, 1.48; 95% CI, 1.30–1.69  
  • LVEF: OR, 0.99; 95% CI, 0.99–0.99  
  • FEV1: OR, 0.99; 95% CI, 0.99–0.99  
  • Recent MI: OR, 3.57; 95% CI, 1.75–7.27  
  • PVD: OR, 1.34; 95% CI, 1.08–1.68 |
| Pick et al, 1997 | Mayo Clinic | United States | 1983–1986 | 321 (160 BITA grafts, 161 SITA grafts) | Multivariable adjustment | Outcome: angina recurrence  
  Female sex: HR, 1.81; 95% CI, 1.22–2.69  
  Obesity: HR, 1.69; 95% CI, 1.21–2.19  
  Preop hypertension: HR, 1.54; 95% CI, 1.87–2.19 |
| Price et al, 2016 | Johns Hopkins Hospital | United States | 1997–2013 | 165 (98 VSRR, 67 Bentall) | PSM and multivariable adjustment | NR |
| Schwann et al, 2016 | Multicenter | United States | 1987–2011 | 5125 (641 BITA grafts, 4484 SITA grafts) | PSM and multivariable adjustment, multivariable adjustment only | NR |
| Stevens et al, 2004 | Montreal Heart Institute | Canada | 1985–1995 | 4382 (1835 BITA grafts, 2547 SITA grafts) | PSM and multivariable adjustment, multivariable adjustment only | Outcome: death  
  • Age: HR, 1.02; 95% CI, 1.01–1.03  
  • DM: HR, 1.81; 95% CI, 1.47–2.23  
  • Prior MI: HR, 1.36; 95% CI, 1.13–1.63  
  • CHF: HR, 2.73; 95% CI, 1.50–4.67  
  • PVD: HR, 2.24; 95% CI, 1.74–2.69  
  • COPD: HR, 1.54; 95% CI, 1.12–2.11  
  • IABP: HR, 1.82; 95% CI, 1.49–2.22  
  • CHF: HR, 1.49; 95% CI, 0.95–2.36  
  • PVD: HR, 1.48; 95% CI, 1.20–1.83  
  • Dyslipidemia: HR, 0.85; 95% CI, 0.70–1.02  
  • COPD: HR, 1.32; 95% CI, 1.03–1.70  
  • Preoperative PCI: HR, 3.28; 95% CI, 1.01–10.6  
  • PVD: HR, 2.56; 95% CI, 1.00–6.53  
  • Any event: HR, 0.98; 95% CI, 0.97–0.99  
  • DM: HR, 1.34; 95% CI, 1.14–1.57  
  • Prior MI: HR, 1.34; 95% CI, 1.18–1.53  
  • Preoperative PCI: HR, 3.28; 95% CI, 1.01–10.6 |

(Continued)


**Table 1. Continued**

| Study | Institution | Country | Study Period | No. of Patients | Type of Adjustment | Effect Estimates of Other Confounders Reported in Study |
|-------|-------------|---------|--------------|-----------------|-------------------|-----------------------------------------------------|
| Suri et al, 2006$^4$ | Mayo Clinic | United States | 1980–1999 | 1411 (1173 MVR, 238 MVR) | Multivariable adjustment | Outcome: death  
  - Age: HR, 1.08; 95% CI, 1.06–1.09  
  - NYHA class: HR, 1.44; 95% CI, 1.23–1.64  
  - CABG: HR, 1.56; 95% CI, 1.27–1.92  
  - Preop LVESD: HR, 1.02; 95% CI, 1.00–1.03 |
| Yang et al, 2018$^5$ | Michigan Medicine | United States | 2001–2017 | 135 (40 VSRR, 95 Bentall) | Multivariable adjustment | Outcome: survival  
  - NYHA functional class (IV or III): RR, 2.69; 95% CI, 1.45–4.99  
  - Older age (>60 y): RR, 2.33; 95% CI, 1.21–4.84  
  - Renal impairment: RR, 2.27; 95% CI, 1.42–3.45 |
| Zhou et al, 2010$^6$ | Centre Hospitalier Universitaire de Rangueil | France | 1995–2002 | 319 (241 MVR, 78 MVR) | Multivariable adjustment | Outcome: death  
  - Age: HR, 1.08; 95% CI, 1.06–1.09  
  - NYHA class: HR, 1.44; 95% CI, 1.23–1.64  
  - CABG: HR, 1.56; 95% CI, 1.27–1.92  
  - Preop LVESD: HR, 1.02; 95% CI, 1.00–1.03 |

ACE indicates angiotensin converting enzyme; BITA, bilateral internal thoracic artery; BMI, body mass index; CABG, coronary artery bypass grafting; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; DM, diabetes mellitus; FEV1, forced expiratory volume; HR, hazard ratio; IABP, intra-aortic balloon pump; ITA, internal thoracic artery; LM, left main; LVEF, left ventricular ejection fraction; LVED, left ventricular end-systolic disease; MI, myocardial infarction; MVr, mitral valve repair; MVR, mitral valve replacement; NR, not reported; NYHA, New York Heart Association; OPCAB, off-pump coronary artery bypass grafting; OR, odds ratio; PSM, propensity score matching; PVD, peripheral vascular disease; RR, relative risk; SITA, single internal thoracic artery; and VSRR, valve-sparing root replacement.

**BITA Versus SITA Grafting**

In the 20 studies comparing BITA versus SITA grafting, the sample size ranged from 321 to 17,609 patients. Three studies were propensity matched, 6 used both propensity matching and multivariable adjustment, and 11 used multivariable adjustment. On average, the observed effect estimates for improved clinical outcomes with BITA versus SITA grafting could be explained by an unmeasured confounder that was associated with both BITA and SITA grafting and the clinical outcomes by an effect size of >3.14. This was lower than the effect size of the other measured confounders in 60.9% of the observational studies comparing BITA versus SITA grafting (E value for lower confidence bound 1.78). The mean E value for effect estimates in propensity-matched and multivariable-adjusted (doubly robust) studies was 2.97: 2.96 for multivariable-adjusted and 2.24 for propensity-matched studies. Details of the average E values for the effect estimates of different clinical outcomes for BITA versus SITA grafting are summarized in Table 2.

**Table 2. Summary of Average E-Value Calculations**

| Variable | VSRR vs Bentall Procedure | MV Repair vs Replacement | BITA vs SITA Grafting |
|----------|---------------------------|--------------------------|-----------------------|
| Number of studies | 4 | 7 | 20 |
| Number of effect estimates | 16 | 14 | 47 |
| Mean E values of effect estimates for different clinical outcomes (mean E value for lower confidence bound) | | | |
| All clinical outcomes | 16.77 (2.44) | 4.32 (1.75) | 3.14 (1.78) |
| Death | 21.35 (1.83) | 4.16 (1.71) | 2.56 (1.74) |
| Cardiac death | 12.98 (-) | 4.03 (1.74) | … |
| Composite outcome | 8.06 (-) | … | 2.69 (1.66) |
| Myocardial infarction | … | … | 3.42 (1.48) |
| Survival | … | 3.17 (1.79) | 2.05 (1.18) |
| Reoperation | 20.92 (3.42) | … | 4.29 (1.77) |
| Mean E-values of effect estimates by adjustment strategy (mean E value for lower confidence bound) | | | |
| Unadjusted | 14.02 (1.81) | 3.33 (2.17) | 5.78 (3.97) |
| Multivariable adjusted | 17.14 (2.73) | 4.49 (1.57) | 2.96 (1.62) |
| Propensity matched | 22.08 (3.79) | 3.59 (2.21) | 2.24 (1.33) |
| Propensity matched and multivariable adjusted | 15.60 (2.15) | … | 2.97 (1.54) |

BITA indicates bilateral internal thoracic artery; SITA, single internal thoracic artery; and VSRR, valve-sparing root replacement.

**DISCUSSION**

Using the E value, we evaluated confounding bias in 31 observational studies on 3 guideline-recommended cardiac surgical procedures. The observed treatment benefit for VSRR versus the Bentall procedure could be explained by an unmeasured confounder associated with both VSRR and clinical outcomes by a risk ratio of 16.76, above the adjusted variables. This was much higher than the treatment-confounder association required to explain the treatment benefit of MV repair over replacement (4.32), and BITA over SITA grafting (3.14). Although this suggests that the evidence supporting VSRR over the Bentall procedure is relatively robust, no observational study showing benefit for VSRR reported the effect sizes for the associations of other covariates with the study outcomes. By comparison, in 33.3% and 60.9% of studies comparing MV repair versus replacement, and BITA versus SITA grafting, respectively, at least 1 study covariate was associated with both the treatment arm and clinical outcomes by an effect size larger than the average E value of these studies.
Studies with smaller sample sizes typically report larger effect estimates, and larger effect estimates yield larger E values. This can spuriously give the impression that these small studies are more robust to unmeasured confounding. For each effect estimate in our analysis, the E values based on the lower bound of the CI were also calculated, as these are less influenced by study size. The lower confidence bound E values demonstrated that the association between VSRR and improved clinical outcomes could lose statistical significance if an unmeasured outcome was associated with both VSRR and the outcomes by a relative effect as low as 2.44. For MV repair and BITA grafting, these E values were even lower, at 1.74 and 1.78, respectively. These data further suggest that the observations in favor of VSRR are relatively more robust to unmeasured confounding than MV repair and BITA-grafting observational evidence. Central to this, however, is the relatively small strengths of the association for the lower confidence bounds, the evidence on all the procedures seems fragile to unmeasured confounding.

Observational studies suggest that BITA grafting can improve patient survival generally based on greater and more-durable graft patency compared with the saphenous vein, as well as increased native atherosclerosis progression associated with saphenous vein grafts. However, randomized data comparing BITA versus SITA grafting report similar results for both strategies. Although reasons inherent to the design and conduct of these trials have been described as possible reasons for this apparent disagreement, the treatment benefit of BITA grafting in observational studies has also been potentially attributed to unmeasured confounders and treatment-allocation bias. The same may be true for the other procedures analyzed. A surgeon’s decision to perform VSRR versus the Bentall procedure is based on careful assessment of the patient’s anatomy and functional status, as well as the surgeon’s expertise in the procedures, all of which are variables that are difficult to measure and account for using statistical adjustment. Similarly, MV repair is more likely to be performed in patients considered to have a longer life expectancy by the operating surgeon.

It is important to note that the use of the E value does not prove that the findings in these comparisons are correct per se. It is theoretically possible that the uncontrolled confounding could work in the opposite direction and be strengthening, instead of denying, the reported associations. However, evaluation using the E value demonstrates that the results reported by the analyzed observational studies are not robust to the idea of uncontrolled confounding possibly explaining the results.

To evaluate the effect of covariate adjustment or propensity matching on reducing confounding bias further, for each surgical comparison, we calculated the average E values for effect estimates stratified by type of adjustment and/or matching used in the observational studies. For both VSRR versus the Bentall procedure, and MV repair versus replacement studies, multivariable adjustment or propensity matching increased the average E value of effect estimates, suggesting increased robustness of effect estimates with adjustment or propensity matching. However, for BITA versus SITA grafting, adjustment or propensity matching of covariates did not increase the E value. These findings suggest that factors unrelated to the measured confounders in BITA- versus SITA-grafting observational studies may have been associated with the outcomes, and that unmatched confounders continue to be present even in matched studies. Furthermore, this suggests that even the best statistical methods currently used to minimize confounding bias in observational studies may have major limitations.

From a practical perspective, the decision to perform a surgical procedure versus another is based on a complex clinical assessment of patients’ characteristics, surgical anatomy, relative effectiveness, and safety of the 2 interventions, as well as the individual surgeon’s experience. Similarly, guideline recommendations are based on the evaluation of the totality of the evidence and the overall risk: benefit ratio. Our data add to the existing knowledge an objective assessment of the solidity of the comparative results for the interventions investigated, but are not enough per se to change recommendations or indicate what intervention to use in clinical practice.

Our study has limitations. Only statistically significant associations were selected, and the use of P values and statistical significance may not be ideal for estimating causal effects. It is possible to apply the E value in the absence of evidence of association to assess how much unmeasured/residual confounding would be required to make a null association clinically significant. However, the E value is only typically applied when claims of associations or treatment benefit are made. We did not also assess for other sources of bias in our study; it is possible that various forms of reporting bias might have been present in the selected studies. It is also possible that the effect estimates could have been biased by measurement error, and we could not examine how the exposures were measured.

In conclusion, the E values for observational evidence supporting use of VSRR, MV repair, and BITA grafting over the Bentall procedure, MV replacement, and SITA grafting, respectively, are relatively low. This
suggests that small-to-moderate unmeasured confounding could explain most of the observed associations for these cardiac surgery procedures.

The E value, or other similar sensitivity analyses, should be part of the reporting of all comparative observational studies.

ARTICLE INFORMATION

Received April 7, 2020; accepted July 21, 2020.

Affiliations

From the Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY (M.G., I.H., N.B.R., A.N., V.W., Y.R., L.N.G.); and Schulich Heart Centre, Sunnybrook Health Science University of Toronto, Toronto, Ontario, Canada (D.T., S.F.).

Sources of Funding

Prof Fremes is supported in part by the Bernard S. Goldman Chair in Cardiovascular Surgery. Dr Tam is supported in part by a Canadian Institutes of Health Research scholarship.

Disclosures

None.

REFERENCES

1. O’Neil M, Berkman N, Hartling L, Chang S, Anderson J, Motu’apuaka M, Guise J-M, McDonagh MS. Observational evidence and strength of evidence domains: case examples. Syst Rev. 2014;3:35.

2. Erbel R, Aboyans V, Boileau G, Bossone E, Bartolomeo RD, Eggebrecht H, Evangelista A, Falk V, Frank H, Gaemperli O, et al. 2014 ESC guidelines on the diagnosis and treatment of arterial diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2873–2926.

3. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Muñoz D, et al. 2017 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2017;38:2739–2791.

4. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Bartolomeo RD, Eggebrecht H, Evangelista A, Falk V, Frank H, Gaemperli O, et al. 2014 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2014;35:2739–2791.

5. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet J-P, Falk V, Head HS, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40:87–165.

6. Gaudino M, Di Franco A, Rahouma M, Tam DY, Iannaccone M, Deb S, D’Ascenzo F, Abouarab AA, Girardi LN, Taggart DP, et al. Unmeasured confounders in observational studies comparing bilateral versus single internal thoracic artery for coronary artery bypass grafting: a meta-analysis. J Am Heart Assoc. 2018;7:e008010. DOI: 10.1161/JAHA.117.008010.

7. Uddin MDJ, Groenwold RHH, Ali MS, de Boer A, Roes KCB, de Groen W, Groenwold RHH, Ali MS, de Boer A, Roes KCB, Westers P. Better ischemic event-free survival after two internal thoracic artery grafts: 13 years of follow-up. Ann Thorac Surg. 2019;108:879–879.

8. Chikwe J, Goldstone AB, Passage J, Anyanwu AC, Seeburger J, Castillo JL, Fisacoufi F, Mohr FW, Adams DH. A propensity score-adjusted retrospective comparison of early and mid-term results of mitral valve repair versus replacement in octogenarians. Eur Heart J. 2011;32:618–626.

9. Endo M, Nishida H, Tomizawa Y, Kanasaki H. Benefit of bilateral over single internal mammary artery grafts for multiple coronary artery bypass grafting. Circulation. 2001;104:2164–2170.

10. Gogbashian A, Sepic J, Soltész EG, Nascimben L, Cohn LH. Operative and long-term survival of elderly is significantly improved by mitral valve repair. Am J Heart. 2008;151:1325–1333.

11. Grau JB, Johnson CK, Kuschner CE, Ferrari G, Shaw RE, Brizzio ME, Zapolanski A. Impact of pump status and conduit choice in coronary artery bypass: a 15-year follow-up study in 1412 propensity-matched patients. J Thorac Cardiovasc Surg. 2015;149:1027–1033.e2.

12. Itoh S, Kimura N, Adachi H, Yamaguchi A. Is bilateral internal mammary arterial grafting beneficial for patients aged 75 years or older? Circ J. 2016;80:1756–1763.

13. Javadikasgari H, Gillinov AM, Idrees JJ, Mihaljevic T, Suri RM, Raza S, Houghtaling PL, Svensson LG, Navia JL, Mick SL, et al. Valve repair is superior to replacement in most patients with coexisting degenerative mitral valve and coronary artery diseases. Ann Thorac Surg. 2017;103:1833–1841.

14. Kelly R, Buth KJ, Légardé J-F. Bilateral thoracic arterial thoracic aorta is superior to other forms of multiple arterial grafting in providing survival benefit after coronary bypass surgery. J Thorac Cardiovasc Surg. 2012;144:1408–1415.

15. Kieser TM, Lewin AM, Graham MM, Martin B-J, Galbraith PD, Rabi DM, Norris CM, Farsis PD, Knudtson ML, Ghali WA, et al. Outcomes associated with bilateral internal thoracic artery grafting: the importance of age. Ann Thorac Surg. 2011;92:1269–1276; discussion 1275–1276.

16. Kinoshita T, Asai T, Suzuki T. Off-pump bilateral skeletonized internal thoracic arterial grafting in patients with chronic kidney disease. J Thorac Cardiovasc Surg. 2015;150:315–321.e3.

17. Kurlansky PA, Traad EA, Dorman MJ, Galbut DL, Zucker M, Ebra G. Thirty-year follow-up defines survival benefit for second internal mammary artery in propensity-matched groups. Ann Thorac Surg. 2010;90:101–108.

18. Lazam S, Vanoverschelde J-L, Tribouilloy C, Grigioni F, Suri RM, Avierinos J-F, de Meester C, Barbieri A, Rusinaru D, Russo A, et al. Twenty-year outcome after mitral repair versus replacement for severe degenerative mitral regurgitation: analysis of a large, prospective, multicenter, international registry. Circulation. 2017;135:410–422.

19. Lee EM, Shapiro LM, Wells FC. Superiority of mitral valve repair in surgery for degenerative mitral regurgitation. Eur Heart J. 1997;18:655–663.

20. Lee H, Cho YH, Sung K, Kim WS, Park KH-II, Jeong DS, Park PW, Lee YT. Clinical outcomes of root reimplantation and Bentall procedure: propensity score matching analysis. Ann Thorac Surg. 2018;106:539–547.

21. Locker C, Schaff HV, Dearani JA, Joyce LD, Park SJ, Burkart HM, Suri RM, Greaslon KL, Stulak JM, Li Z, et al. Multiple arterial grafts improve
late survival of patients undergoing coronary artery bypass graft surgery: analysis of 8622 patients with multivessel disease. Circulation. 2012;126:1023–1030.

32. Medalion B, Mohr R, Ben-Gai Y, Nesher N, Kramer A, Eliyahu S, Pevni D. Arterial coronary artery bypass grafting is safe and effective in elderly patients. J Thorac Cardiovasc Surg. 2015;150:607–612.

33. Navia DO, Vrancic M, Piccinini F, Camporotondo M, Dorsa A, Espinoza J, Benzaon M, Camou J. Myocardial revascularization exclusively with bilateral internal thoracic arteries in T-graft configuration: effects on late survival. Ann Thorac Surg. 2016;101:1775–1781.

34. Ouzounian M, Rao V, Manihot C, Abraham N, David C, Feindel CM, David TE. Valve-sparing root replacement compared with composite valve graft procedures in patients with aortic root dilatation. J Am Coll Cardiol. 2016;68:1838–1847.

35. Parsa CJ, Shaw LK, Rankin JS, Daneshmand MA, Gaca JG, Milano CA, Glower DD, Smith PK. Twenty-five-year outcomes after multiple internal thoracic artery bypass. J Thorac Cardiovasc Surg. 2016;101:1775–1781.

36. Pettinari M, Sergeant P, Meuris B. Bilateral internal thoracic artery grafting increases long-term survival in elderly patients. Eur J Cardiothorac Surg. 2015;47:703–709.

37. Price J, Magruder JT, Young A, Grimm JC, Patel ND, Alejo D, Dietz HC, Vicella LA, Cameron DE. Long-term outcomes of aortic root operations for Marfan syndrome: a comparison of Bentall versus aortic valve-sparing procedures. J Thorac Cardiovasc Surg. 2016;151:330–338.

38. Schwann TA, Hashim SW, Badour S, Obeid M, Engoren M, Tranbaugh RF, Bonnell MR, Habib RH. Equipoise between radial artery and right internal mammary artery grafts: 10-year outcome analysis. Ann Thorac Surg. 1997;64:599–605.

39. Price J, Magruder JT, Young A, Grimm JC, Patel ND, Alejo D, Dietz HC, Vicella LA, Cameron DE. Long-term outcomes of aortic root operations for Marfan syndrome: a comparison of Bentall versus aortic valve-sparing procedures. J Thorac Cardiovasc Surg. 2016;151:330–338.

40. Schwann TA, Hashim SW, Badour S, Obeid M, Engoren M, Tranbaugh RF, Bonnell MR, Habib RH. Equipoise between radial artery and right internal mammary artery grafts: 10-year outcome analysis. Ann Thorac Surg. 1997;64:599–605.

41. Suri RM, Schiff HV, Dearani JA, Sundt TM, Daly RC, Mullany CJ, Enriquez-Sarano M, Orszulak TA. Survival advantage and improved durability of mitral repair for leaflet prolapse subsets in the current era. Ann Thorac Surg. 2006;82:819–826.

42. Yang B, Patel HJ, Sorek C, Hornsby WE, Wu X, Ward S, Thomas M, Dracoll A, Waiteley VA, Norton EL, et al. Sixteen-year experience of david and Bentall procedures in acute type A aortic dissection. Ann Thorac Surg. 2018;105:779–784.

43. Zhou Y, Leobon B, Berthoumieu P, Roux D, Glock Y, Mei Y, Wang Y, Fournial G. Long-term outcomes following repair or replacement in degenerative mitral valve disease. Thorac Cardiovasc Surg. 2010;58:415–421.

44. Tatoulis J, Buxton BF, Fuller JA. Patencies of 2127 arterial to coronary conduits over 15 years. Ann Thorac Surg. 2004;77:93–101.

45. Gaudino M, Antoniades C, Benedetto U, Deb S, Di Franco A, Di Giammarco G, Femes S, Glineur D, Grau J, He G-W, et al. Mechanisms, consequences, and prevention of coronary graft failure. Circulation. 2013;126:1742–1764.

46. Myers WC, Berg R, Ray JF, Douglas-Jones JW, Maki HS, Ulmer RH, Chatman BR, Reinhart RA. All-artery multigraft coronary artery bypass grafting with only internal thoracic arteries possible and safe: a randomized trial. Surgery. 2000;128:650–659.

47. Gaudino M, Cellini C, Pragliola C, Trani C, Burzotta F, Schiavioli G, Nasso G, Possati G. Arterial versus venous bypass grafts in patients with in-stent restenosis. Circulation. 2005;112:266–269.

48. Taggart DP, Benedetto U, Gerry S, Altman DG, Gray AM, Lees B, Gaudino M, Zamvar V, Bochenek A, Buxton B, et al. Bilateral versus single internal-thoracic-artery grafts at 10 years. N Engl J Med. 2019;380:437–446.

49. Gaudino M, Rahouma M, Hameed I, Khan FM, Taggart DP, Flather M, Biondi-Zoccai G, Femes SE. Disagreement between randomized and observational evidence on the use of bilateral internal thoracic artery grafting: a meta-analytic approach. J Am Heart Assoc. 2019;8:e014638. DOI: 10.1161/JAHA.119.014638.

50. Ioannidis JPA, Tan YJ, Blum MR. Limitations and misinterpretations of E-values for sensitivity analyses of observational studies. Ann Intern Med. 2019;170:108–111.